FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912789183> ?p ?o ?g. }

• W2912789183 endingPage "S050" @default.
• W2912789183 startingPage "S049" @default.
• W2912789183 abstract "Tofacitinib is an oral, small-molecule JAK inhibitor approved in several countries for the treatment of ulcerative colitis (UC). We evaluated efficacy and safety of tofacitinib in patients with clinical response, but not remission, after 52 weeks of maintenance therapy in the OCTAVE Sustain study, who subsequently received tofacitinib 10 mg twice daily (BID) in an ongoing, open-label, long-term extension (OLE) study (OCTAVE Open; data as of November 2017).1 We evaluated clinical response, remission, and mucosal healing based on Mayo score (using local endoscopic reading and non-responder imputation) in patients with clinical response but not remission (based on central endoscopic reading at Week 52 of OCTAVE Sustain) who received tofacitinib 10 mg BID in the OLE study. Efficacy is reported at Month (M) 2, M12, and M24 of the OLE by subgroups of prior tumour necrosis factor inhibitor (TNFi) failure (yes/no). Safety was assessed throughout the study. Eighty patients were included in the analysis (18 received placebo in OCTAVE Sustain; 28 received tofacitinib 5 mg BID; 35 received 10 mg BID; 1 patient was randomised into OCTAVE Sustain in error and received 10 mg BID in the OLE). Thirty-eight of 82 (46.3%) had prior TNFi failure per induction baseline. Clinical response at M24 was maintained by 69.5% (41/59), 65.4% (17/26), and 72.7% (24/33) of patients overall, and with and without prior TNFi failure, respectively. By M2, the proportion of patients who had improved to remission, overall and for patients with and without prior TNFi failure, was 58.5% (48/82), 60.5% (23/38), and 56.8% (25/44), respectively. M2 remission rates were 77.8% (14/18) for patients who had received placebo in OCTAVE Sustain, 57.1% (16/28) for patients who had received 5 mg BID, and 50.0% (18/36) for patients who had received 10 mg BID (Figure 1). A summary of safety in the OLE clinical responder subpopulation is presented (Table 1). Over 50% of patients with UC who completed OCTAVE Sustain as clinical responders improved to remission within 2 months of receiving 10 mg BID in the OLE study. Efficacy was observed regardless of prior TNFi failure status. No new safety concerns associated with tofacitinib emerged with regard to the overall study population.1 Abstract DOP041–Figure 1. Rates of clinical response, remission, and mucosal healing in the OLE study maintenance clinical responder subpopulationa overall and by maintenance treatment received in the prior OCTAVE sustain study, NRI. aPatients who received tofacitinib 10 mg BID and were in clinical response (neither in remission nor treatment failures), based on central endoscopic reading, at the OLE study baseline (all receiving tofacitinib 10 mg BID in the OLE study). Data as of November 2017 data cut-off. Data for Month 0 (ie, Weak 52 of OCTAVE sustain) are based on central read endoscopy; all other data are based on local read endoscopy. Remission was defined as a total Mayo score of ≤2 with no individual subscore >1, and a rectal bleeding subscore of 0. Mucosal healing was defined by a Mayo endoscopic subscore ≤1. Clinical response was defined as a decrease from induction study baseline total Mayo score of ≥3 points and ≥30%, plus a decrease in rectal bleeding subscore of ≥1 point or an absolute rectal bleeding subscore of 0 or 1.BID, twice daily; N, number of patients in the specified category with non-missing values; NRI, non-responder imputation; OLE, open-label, long-term extension; pts,, patients. Abstract DOP041 – Table 1. Summary of safety in the OLE study for the maintenance clinical responder subpopulation. Reference 1. Lichtenstein GR. Tofacitinib, an oral Janus kinase inhibitor, in the treatment of ulcerative colitis: open-label, long-term extension study. Am J Gastroenterol 2017;112(S1): Abstract 714." @default.
• W2912789183 created "2019-02-21" @default.
• W2912789183 creator A5000141404 @default.
• W2912789183 creator A5008838958 @default.
• W2912789183 creator A5020827915 @default.
• W2912789183 creator A5024936486 @default.
• W2912789183 creator A5031236528 @default.
• W2912789183 creator A5035586844 @default.
• W2912789183 creator A5051873692 @default.
• W2912789183 creator A5071194126 @default.
• W2912789183 creator A5074003306 @default.
• W2912789183 creator A5083147613 @default.
• W2912789183 creator A5091365382 @default.
• W2912789183 date "2019-01-25" @default.
• W2912789183 modified "2023-09-26" @default.
• W2912789183 title "DOP41 Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: data from the OCTAVE studies" @default.
• W2912789183 doi "https://doi.org/10.1093/ecco-jcc/jjy222.075" @default.
• W2912789183 hasPublicationYear "2019" @default.
• W2912789183 type Work @default.
• W2912789183 sameAs 2912789183 @default.
• W2912789183 citedByCount "3" @default.
• W2912789183 countsByYear W29127891832020 @default.
• W2912789183 countsByYear W29127891832022 @default.
• W2912789183 crossrefType "journal-article" @default.
• W2912789183 hasAuthorship W2912789183A5000141404 @default.
• W2912789183 hasAuthorship W2912789183A5008838958 @default.
• W2912789183 hasAuthorship W2912789183A5020827915 @default.
• W2912789183 hasAuthorship W2912789183A5024936486 @default.
• W2912789183 hasAuthorship W2912789183A5031236528 @default.
• W2912789183 hasAuthorship W2912789183A5035586844 @default.
• W2912789183 hasAuthorship W2912789183A5051873692 @default.
• W2912789183 hasAuthorship W2912789183A5071194126 @default.
• W2912789183 hasAuthorship W2912789183A5074003306 @default.
• W2912789183 hasAuthorship W2912789183A5083147613 @default.
• W2912789183 hasAuthorship W2912789183A5091365382 @default.
• W2912789183 hasBestOaLocation W29127891831 @default.
• W2912789183 hasConcept C126322002 @default.
• W2912789183 hasConcept C141071460 @default.
• W2912789183 hasConcept C142724271 @default.
• W2912789183 hasConcept C204787440 @default.
• W2912789183 hasConcept C27081682 @default.
• W2912789183 hasConcept C2776694085 @default.
• W2912789183 hasConcept C2777575956 @default.
• W2912789183 hasConcept C2778283404 @default.
• W2912789183 hasConcept C2778886723 @default.
• W2912789183 hasConcept C2779134260 @default.
• W2912789183 hasConcept C2780479503 @default.
• W2912789183 hasConcept C3019800554 @default.
• W2912789183 hasConcept C535046627 @default.
• W2912789183 hasConcept C71924100 @default.
• W2912789183 hasConcept C90924648 @default.
• W2912789183 hasConceptScore W2912789183C126322002 @default.
• W2912789183 hasConceptScore W2912789183C141071460 @default.
• W2912789183 hasConceptScore W2912789183C142724271 @default.
• W2912789183 hasConceptScore W2912789183C204787440 @default.
• W2912789183 hasConceptScore W2912789183C27081682 @default.
• W2912789183 hasConceptScore W2912789183C2776694085 @default.
• W2912789183 hasConceptScore W2912789183C2777575956 @default.
• W2912789183 hasConceptScore W2912789183C2778283404 @default.
• W2912789183 hasConceptScore W2912789183C2778886723 @default.
• W2912789183 hasConceptScore W2912789183C2779134260 @default.
• W2912789183 hasConceptScore W2912789183C2780479503 @default.
• W2912789183 hasConceptScore W2912789183C3019800554 @default.
• W2912789183 hasConceptScore W2912789183C535046627 @default.
• W2912789183 hasConceptScore W2912789183C71924100 @default.
• W2912789183 hasConceptScore W2912789183C90924648 @default.
• W2912789183 hasIssue "Supplement_1" @default.
• W2912789183 hasLocation W29127891831 @default.
• W2912789183 hasOpenAccess W2912789183 @default.
• W2912789183 hasPrimaryLocation W29127891831 @default.
• W2912789183 hasRelatedWork W2587875644 @default.
• W2912789183 hasRelatedWork W2611548364 @default.
• W2912789183 hasRelatedWork W2911592213 @default.
• W2912789183 hasRelatedWork W2912789183 @default.
• W2912789183 hasRelatedWork W3026914928 @default.
• W2912789183 hasRelatedWork W3087427934 @default.
• W2912789183 hasRelatedWork W3208135804 @default.
• W2912789183 hasRelatedWork W4242153315 @default.
• W2912789183 hasRelatedWork W4245715596 @default.
• W2912789183 hasRelatedWork W4282971104 @default.
• W2912789183 hasVolume "13" @default.
• W2912789183 isParatext "false" @default.
• W2912789183 isRetracted "false" @default.
• W2912789183 magId "2912789183" @default.
• W2912789183 workType "article" @default.